Please ensure Javascript is enabled for purposes of website accessibility

Why Invitae's Q4 Results Didn't Fire Up Investors

By Keith Speights - Feb 18, 2021 at 6:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's revenue soared, but so did its expenses.

Invitae (NVTA -9.47%) delivered a sizzling performance in 2020, with its shares skyrocketing 159%. That sizzle fizzled somewhat last month, though, after the medical genetics company announced a dilution-causing stock offering.

The company reported its fourth-quarter results after the market closed on Wednesday. The healthcare stock slipped a little in after-hours trading. Here are the highlights from Invitae's latest quarterly update.

Scientists in front of computer screens with DNA displayed on one screen

Image source: Getty Images.

By the numbers

Invitae reported revenue in the fourth quarter of $100.4 million, a 51% year-over-year jump. This result topped the Wall Street consensus estimate of $98.4 million.

The company announced a net loss in the fourth quarter of $241 million, or $1.34 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Invitae posted a GAAP net loss of $76.9 million, or $0.79 per share.

Invitae's bottom line looked somewhat better on an adjusted non-GAAP basis. The company recorded a Q4 adjusted net loss of $113.1 million, or $0.63 per share. In the prior-year period, Invitae's net loss totaled $61 million. Analysts had projected a Q4 net loss of $0.55 per share.

Behind the numbers

The company reported 659,000 in billable test volume for full-year 2020. More than 36% of that total (238,000) came in the fourth quarter.

There's no secret behind much of Invitae's growth. The medical genetics company completed the acquisition of ArcherDX on Oct. 5, 2020. This deal gave Invitae a broader offering of testing services.

However, the ArcherDX transaction was also largely responsible for Invitae's big increase in expenses during the fourth quarter. The company's general and administrative expenses soared more than tenfold year over year to $242.6 million. Most of this increase was directly related to the ArcherDX acquisition.

Invitae's research and development costs and selling and marketing expense also jumped significantly compared to the prior-year period. Again, the ArcherDX deal was a key factor behind these increases.

Looking ahead

The company continues to project revenue growth of between 50% and 60% annually over the next few years. Invitae looks for full-year 2021 revenue of more than $450 million.

CEO Sean George stated that Invitae is "committed to maintaining the pace [the company has] set, making it ever-easier to integrate genetic information into healthcare decision-making by clinicians and patients at all stages of life." With the genetic testing market growing, Invitae should have strong growth prospects for the foreseeable future.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invitae Stock Quote
Invitae
NVTA
$3.44 (-9.47%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.